# Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer

> **NCT00894504** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 71 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Panitumumab
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00894504
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2015-05-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00894504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00894504, "Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00894504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*